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Purpose: In primary care, initial diagnosis of community-acquired pneumonia (CAP) is
made on clinical judgment without radiological conﬁrmation or knowledge of the causative
organism. Use of CRB65 score has been recommended for assessing the severity of CAP and
thereby determining clinical management, but it is not known how frequently these scores
are used in primary care.
Patients and methods: Primary care consultations in adults with a diagnostic code for
CAP between 1 January 2009 and 31 December 2016 were extracted from the Optimum
Patient Care Research Database, which at the time of data extraction had over 3.4 million
patients in the UK. Episodes without antibiotic prescription on day of diagnosis were
excluded, as were records describing past events. Patients admitted to hospital on day of
diagnosis were excluded, but were included in exploratory analysis of CRB65 recording.
Results: In total, 4734 episodes of CAP in adults managed in primary care between 1
January 2009 and 31 December 2016 were included. A range of investigations/observations
were recorded, including pulse rate (10.7%), chest examinations (9.1%) and blood tests
(5.4%). CRB65 scores were recorded in 19 (0.4%) episodes of CAP, 17 of which were after
the publication of the NICE guidelines in December 2014. CRB65 recording was no more
frequent in 3819 episodes referred to hospital (12, 0.3%; p=0.63), but where recorded,
CRB65 scores were higher (Median: 1.0 [interquartile range: 0.5–1.0] vs 2.0 [interquartile
range: 1.0–2.0], p=0.04). The most commonly prescribed antibiotic was amoxicillin (40.3%),
and 85.9% of episodes had a prescription length of seven days.
Conclusion: CRB65 scores are seldom recorded in UK primary care. Given that these
scores are embedded in UK guidelines, further work is required to assess feasibility and
barriers to use of CRB65 scores in primary care.
Keywords: lower-respiratory tract infection, antibiotics, antimicrobials, guidelines
adherence, CRB65
Introduction
Community-acquired pneumonia (CAP) is a leading infectious cause of death in the
UK.1 In the primary care setting, initial diagnosis is typically made on clinical
judgment without radiological conﬁrmation or knowledge of the causative
organism.2 For patients presenting in primary care, the decision to treat in the
community or refer for hospital admission requires an assessment of CAP severity.
In severe CAP, delays in admission to the intensive care unit are associated with
increased mortality.3,4
Use of severity scores may act as an adjunct to clinical decision-making, aiding
the identiﬁcation of patients at high risk of death.5,7 However, many of these scores
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include parameters that cannot readily be assessed in pri-
mary care, such as urea included in the CURB65 score.8
Consequently, the CRB65 score has been developed for
use in primary care.
The CRB65 score assigns one point to each of: confusion,
raised respiratory rate (30 breaths per minute or more), low
blood pressure (diastolic 60 mmHg or less, or systolic less
than 90 mmHg) and age 65 years or more, and the total score
can be used to predict 30-day mortality. CAP patients’ 30-
day mortality risk is then calculated as 0 (low risk – less than
1%mortality risk), 1–2 (intermediate risk – 1–10%mortality
risk) and 3–4 (high risk – more than 10% mortality risk).8
In 2009, the CRB65 score was recommended for use in
primary care by the British Thoracic Society (BTS) guidelines
and quality standards on themanagement of CAP in adults.9 In
December 2014, the CRB65 score was incorporated into
National Institute for Health and Care Excellence (NICE)
guidelines Pneumonia in Adults: Diagnosis and
Management.10 The guidelines suggest CRB65 scores be
used alongside clinical judgment in primary care, and that
hospital-based care be considered for all patients with a
CRB65 score of one or more, and particularly for those with
a score of two or more. Furthermore, the guidelines recom-
mend a 5-day course of a single antibiotic for patients with
low-severity CAP, while a 7- or 10-day course of antibiotic
therapy is recommended for moderate- to high-severity CAP.
The use of CRB65 scores is also included in the most recent
NICE quality standards for the management of pneumonia in
adults,11 which states that adults diagnosed with CAP in
primary care “should have a mortality risk assessment using
the CRB65 score”. Finally, in January 2019, NICE released
draft guidance on antimicrobial prescribing for CAP,12 in
which antibiotic prescription is based on severity as deter-
mined by clinical judgement and CRB65 scores.
Despite studies on the accuracy of CRB65 scores in
determining severity,6,13 and these scores being embedded
in UK guidance,9,12 it is not known to what degree these
scores are used in UK primary care. We set out to assess the
use of CRB65 scores in patients diagnosed with CAP in UK
primary care.
Materials And Methods
This retrospective observational database study aimed to
investigate the management of CAP in primary care in the
UK, focusing on the recording of CRB65 scores and pre-
scription of antibiotics. The study was performed using elec-
tronic medical records obtained from the Optimum Patient
Care Research Database (OPCRD: https://opcrd.co.uk/). The
OPCRD is a quality-controlled, longitudinal, primary care,
respiratory-focused database containing pseudonymised data
from general practices in the UK. At the time of this study, it
contained data of over 3.4 million patients and now contains
data of 6.3 million patients from over 600 general practices.
Because in the UK, people are required to register with a
primary care physician in order to receive health care, UK
primary care databases are widely considered to be essen-
tially population-based.14
The study protocol was approved by the Anonymised
Data and Protocol Transparency (ADEPT) committee
(ADEPT0817) and registered with the European Network of
Centres for Pharmacoepidemiology and Phamacovigilance
(ENCePP, EUPAS28667).
Record Selection
Primary care consultations in adults with a diagnostic code
for CAP (Appendix 1) between 1 January 2009 and 31
December 2016 and with a minimum of 28 days of contin-
uous medical record prior to and after the diagnoses were
extracted from the OPCRD. The study period covered both
the publication of the BTS CAPGuidelines in 20099 and the
publication of the NICE Quality Standard in December
2014.10 To maintain our focus on newly diagnosed cases
of CAP managed in primary care, consultations were
excluded if they had no recording of an antibiotic prescrip-
tion on the day of diagnosis (on the assumption that they led
to a hospital referral) or were summaries of past events.
Consultations resulting in hospitalization were excluded
from the main analysis as the timing of their hospitalization
and data on their management was not available. However,
this subset of patients was included in exploratory analysis
of clinical details and CRB65 recording.
Consultations were grouped into episodes of CAP per
patient. A new episode was deﬁned as a consultation for
CAP at least 180 days after any prior consultation for CAP
for an individual patient. For each episode, an evaluation
period consisting of an index date of the day of diagnosis,
a baseline period of 28 days prior to diagnosis and out-
come period of 28 days after diagnosis was considered.
Data Analysis
Data were analysed using R (version 3.4.0) and RStudio
(version 1.0.143). The primary outcomes were CRB65
recording and class and length of antibiotic prescription.
Demographic and clinical characteristics were summarised
for both included and excluded CAP episodes. Statistical
analysis utilised Chi-squared test for categorical variables,
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one-way ANOVA for continuous variables and Wilcox for
differences in medians. Kendall’s correlation was used to
assess trends over time. Multivariable logistic regression
was used to assess determinants of CRB65 recording.
Variables showing an association with CRB-65 recording
with a p-value of less than 0.2 in single variable analysis
were included in the original logistic regression model.
Variables showing no signiﬁcant association (p>0.05)
were removed in a stepwise fashion.
Results
A total of 49,863 new episodes of CAP were recorded in
adults between 1 January 2009 and 31 December 2016,
of which 36,011 had the minimum required continuous
medical records (Figure 1). Of these, 21,802 (60.5%)
were excluded because no antibiotic prescription was
given in primary care and 5656 (15.7%) because the
primary consultation was a summary of a past event. A
further 3819 episodes had a referral to secondary care on
the index date and so were only included in the explora-
tory analysis. The ﬁnal study population, managed in
primary care, consisted of 4734 discrete episodes of
CAP from 4595 patients. Most patients had only one
episode in the study period (4467, 97.2%) and the major-
ity of episodes of CAP consisted of one consultation
(3434, 72.5%). Of the 1300 episodes with more than
one consultation, the majority had their second consulta-
tion in the outcome period (1134, 87.2%). The median
time to second consultation in these episodes was 7 days
(interquartile range [IQR]: 3–11). Of those with consulta-
tions for CAP in the outcome period, the majority had
one (686, 60.5%) or two (263, 23.2%).
The incidence of CAP managed in primary care
(n=4734) over the study period was 21.7 (95% conﬁdence
interval [CI]: 21.1–22.3) episodes per 100,000 patient-
years in the database. Incidence of CAP managed in pri-
mary care declined over the study period (p<0.001), and
the absolute number of episodes had marked seasonality,
with winter peaks in all years (Figure 2).
Patient Characteristics
The study population of adult patients diagnosed with
CAP (n=4734) had a mean age of 61.6 (standard deviation
[SD]: ±19.3), and 46.0% (n=2179) were male. The cumu-
lative incidence of CAP per 100,000 over the study period
was similar between genders (male: 100.8, 95% CI: 96.6–
105.1; females: 105.3, 95% CI: 101.2–109.4, Figure 3).
Obesity was recorded in 24.5% (n=1158) and overweight
in 28.6% (n=1355), with missing BMI data in 14.0%. 19.1%
(n=904) current smokers and 36.5% (n=1729) were ex-smo-
kers. The most common comorbidities prior to CAP diag-
nosis were gastro-oesophageal reﬂux disease (30.1% of
which 23.3% [1102/1427] had active disease in the baseline
period), cardiovascular disease (26.7%, n=1263), eczema
(26.6% of which 0.5% [23/1258] had active disease), rhinitis
(23.0% of which 8.5% [401/1088] had active disease) and
asthma (22.9%, n=1086; Table 1). A COPD diagnosis was
recorded in 13.5% (n=639) of episodes.
Figure 1 Flowchart of inclusion and exclusion criteria.
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Assessment Of CAP In Primary Care
On the index date, a suspected organism was recorded for
13.5% (n=637) episodes, and 57.4% (n=2719) had details
on the location or type of pneumonia. Blood pressure
(17.6%, n=832), pulse rate (10.7%, n=508) and chest
examination (9.1%, n=432) were the most frequently
recorded observations on index date. Oxygen saturation
was recorded in 7.1% (n=337) of episodes, blood tests in
5.4% (n=257) of episodes and urine tests in 1.3% (n=62).
Radiology requests were recorded in 4.8% (n=228) on the
day of diagnosis and 7.5% (354) in the 14 days following
diagnosis.
CRB65 Recording
CRB65 was not recorded in the evaluation period (28 days
before and 28 days after the index date) in 4715 episodes
of CAP. In 19 episodes (0.4%), CRB65 scores were
recorded on index date, of which ﬁve episodes had a
score of zero, 11 had a score of one and three had a
score of two. Of these, 14 episodes also had CRB65 scores
recorded in the baseline period (28 days before the index
date) and one episode had a CRB65 score recorded in the
outcome period (28 days after the index date).
In episodes where CRB65 scores were not recorded, 95
episodes had three components of CRB65 (confusion,
respiratory rate, blood pressure and age) recorded indivi-
dually, and one episode had all four components recorded.
Further, two episodes for which CRB65 were recorded
also had three or more components listed individually.
The majority of episodes with three or more components
recorded (79/98, 80.6%) had a calculated CRB65 score of
less than two (range: 0–3). The least recorded components
were presence/absence of confusion, recorded in 11 epi-
sodes (0.2%) and respiratory rate, recorded in 170 (3.6%)
episodes.
The recording of both CRB65 and their components
improved over time. The recording of CRB65 scores was
signiﬁcantly higher after the publication of the NICE
guidelines in December 2014 (2015–2016: 17/740 [2.3%;
95% CI: 1.3–3.7%]) than beforehand (2009–2014: 2/3994
[0.1%; 95% CI: 0.001–0.2%]; p<0.001; Figure 4). The two
episodes with CRB65 score recorded prior to 2015
occurred in January and December 2014. Similarly,
recording of at least three components of CRB65 was
signiﬁcantly higher in 2015–2016 (32/740 [4.3%; 95%
CI: 3.0–6.1%]) than in the years prior (66/3994 [1.7%;
95% CI: 1.3–2.1%], p<0.001, Figure 4).
In multivariable logistic regression, CRB65 scores or
three or more components were more often recorded in
episodes of CAP in older patients, those who had an LRTI
consultation in the baseline period and those with eosino-
philia (Tables 2 and 3).
Antibiotic Treatment
A consultation for lower respiratory tract infection
(LRTI) was recorded in the baseline period in 11.2% of
episodes, of which 79.4% (420/529) were prescribed
antibiotics. On index date, 91.7% (n=4342) of episodes
had a prescription for a single antibiotic and 8.3%
(n=392) for multiple antibiotics. Amoxicillin was the
most commonly prescribed single antibiotic (44.0%;
Figure 2 Trends in episodes of CAP in primary care from 2009 to 2016, n=4734.
Figure 3 Cumulative incidence of episodes of CAP per 100,000 active patients in
the OPCRD database, over the eight years of study.
Launders et al Dovepress
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Table 1 Baseline Demographic And Clinical Information For The Study Population And Excluded Episodes Referred To Hospital
Variable Included Episodes Managed In
Primary Care
Excluded Episodes Referred
To Hospital
p-Value*
Number of records, n (%) 4734 (100) 3819 (100)
Age group: n (%)
18–44 years 1050 (22.2) 418 (10.9) <0.001
45–64 years 1399 (29.6) 758 (19.8)
65–84 years 1720 (36.3) 1773 (46.4)
85+ years 565 (11.9) 870 (22.8)
Mean age 61.6 (±19.3) 70.1 (±18.1) <0.001
Male gender: n (%) 2179 (46.0) 1917 (50.2) <0.001
Season: n (%) <0.001
Autumn 1094 (23.1) 890 (23.3)
Winter 1654 (34.9) 1184 (31.0)
Spring 1209 (25.5) 1029 (26.9)
Summer 777 (16.4) 716 (18.7)
BMI class: n (%) <0.001
Underweight (<18.5) 179 (3.8) 197 (5.2)
Normal (≥18.5 and <25) 1377 (29.1) 1261 (33.0)
Overweight (≥25 and <30) 1355 (28.6) 1014 (26.6)
Obese (>30) 1158 (24.5) 887 (23.2)
Missing 665 (14.0) 460 (12.0)
BMI: Mean (SD) 27.4 (±6.7) 27.0 (±6.7) 0.012
Smoking status: n (%) <0.001
Non-smoker 2046 (43.2) 1582 (41.4)
Current smoker 904 (19.1) 636 (16.7)
Ex-smoker 1729 (36.5) 1489 (39.0)
Missing 55 (1.2) 112 (2.9)
COPD diagnosed before or at index: n (%) 639 (13.5) 806 (21.1) <0.001
Asthma: n (%)
Diagnosed before or at index, unresolved 1086 (22.9) 726 (19.0) <0.001
Resolved 200 (4.2) 129 (3.4)
Other chronic respiratory condition, ever
diagnosed: n (%)
312 (6.6) 545 (14.3) <0.001
Bronchiectasis, ever diagnosed: n (%) 129 (2.7) 154 (4.0) <0.001
Cardiovascular disease, ever diagnosed: n (%) 1263 (26.7) 1845 (48.3) <0.001
Ischemic heart disease, ever diagnosed: n (%) 575 (12.1) 876 (22.9) <0.001
Congestive heart failure, ever diagnosed: n (%) 268 (5.7) 412 (10.8) <0.001
Myocardial infarction, ever diagnosed: n (%) 287 (6.1) 431 (11.3) <0.001
Hypertension, ever diagnosed: n (%) 87 (1.8) 187 (4.9) <0.001
Diabetes mellitus, ever diagnosed: n (%) 550 (11.6) 714 (18.7) <0.001
(Continued)
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1908/4342), while amoxicillin plus clarithromycin was
the most common combination where multiple antibiotics
were prescribed (46.4%, 179/392, Table 4). While four of
the ﬁve episodes with a CRB65 score of zero were pre-
scribed antibiotics in line with the draft NICE
guidelines,12 this was the case for only four of the 14
records with CRB65 scores of 1 or 2 (Table 5). Where the
duration of antibiotic prescription on the day of CAP
diagnosis was known, the mean duration was seven
days (sd±2.6) and 76.5% (2599/3400) of episodes had a
seven-day prescription.
Episodeswheremultiple antibiotics were prescribed were
more likely to have a follow-on consultation in the outcome
period for LRTI (38.3% [95% CI: 33.4–43.3%] vs 28.7%
[95% CI: 27.3–30.0%], p<0.001) or CAP (32.1% [95% CI:
27.5–37.0%] vs 23.2% [95% CI: 22.0–24.5%], p<0.001)
than those where single antibiotics were prescribed.
Exploratory Analysis Of Patients Managed
In Primary Care And Those Referred To
Secondary Care
Patient characteristics of the study population managed in
primary care differed signiﬁcantly to the 3819 patients
referred to hospital on day of CAP diagnosis (Table 1).
Those managed in primary care had a lower mean age,
comprised a higher proportion of females and were more
likely to be current or non-smokers than episodes referred
to hospital, while those hospitalized were more likely to be
ex-smokers (Table 1). Episodes managed in primary care
also had a lower proportion of cardiovascular disease
(26.7% [95% CI: 25.4–28.0%] vs 48.3% [95% CI: 46.7–
49.9%]; p<0.001), pre-existing COPD (13.5% [95% CI:
12.5–14.5%] vs 21.1% [95% CI: 19.8–22.4]; p<0.001) and
other chronic respiratory conditions (6.6% [95% CI: 5.9–
7.3%] vs 14.3% [95% CI: 13.2–15.4%]; p<0.001) but a
higher proportion pre-existing asthma (22.9% [95% CI:
Table 1 (Continued).
Variable Included Episodes Managed In
Primary Care
Excluded Episodes Referred
To Hospital
p-Value*
Rhinitis: n (%)
Active in baseline 401 (8.5) 406 (10.6) <0.001
Ever diagnosed 1088 (23.0)
Eczema: n (%)
Active in baseline 23 (0.5) 168 (4.4) <0.001
Ever diagnosed 1258 (26.6)
Eosinophilia in baseline: n (%) 648 (13.7) 974 (25.5) <0.001
Gastro-oesophageal reﬂux disease: n (%)
Active in baseline 1102 (23.3) 1307 (34.2) <0.001
Ever diagnosed 1427 (30.1)
Antibiotic prescription on day of diagnosis, n
(%)
4734 (100) 95 (2.5)
Note: *Chi-squared or Fishers exact tests for all categorical variables, one-way ANOVA for continuous variables and Wilcox for median CRB65 score.
Abbreviations: BMI, Body mass index; COPD, Chronic obstructive pulmonary disease.
Figure 4 Percentage of episodes recording CRB65 or at least three components of
CRB65 per year.
Note: Shaded areas: 95% conﬁdence intervals.
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Table 2 Determinants Of Or Three Or More Components Of CRB65 Recording: Single Variable Analysis
CRB65 or 3 CRB65 Components
Recorded: n (%)
CRB65 Not
Recorded: n (%)
Risk Ratio 95% Conﬁdence
Intervals
p-Value
Grouped year:
2009–2013 50 (1.4) 3443 (98.6) REFERENCE
2014–2016 65 (5.2) 1176 (94.8) 3.66 2.55–5.26 <0.001
Season:
Winter 45 (2.7) 1609 (97.3) REFERENCE
Spring 27 (2.2) 1182 (97.8) 0.82 0.51–1.32 0.411
Summer 19 (2.4) 758 (97.6) 0.90 0.53–1.53 0.693
Autumn 24 (2.2) 1070 (97.8) 0.81 0.49–1.32 0.387
Age:
18–44 13 (1.2) 1037 (98.8) REFERENCE
45–64 31 (2.2) 1368 (97.8) 1.79 0.94–3.40 0.071
65–84 51 (3.0) 1669 (97.0) 2.39 1.31–4.38 0.003
85+ 20 (3.5) 545 (96.5) 2.86 1.43–5.70 0.001
Gender:
Male 54 (2.5) 2125 (97.5) REFERENCE
Female 61 (2.4) 2494 (97.6) 0.96 0.67–1.38 0.840
BMI:
Normal 29 (2.1) 1347 (97.9) REFERENCE
Obese 27 (2.3) 1131 (97.7) 1.11 0.66–1.86 0.700
Overweight 40 (2.9) 1315 (97.0) 1.40 0.87–2.25 0.159
Under weight 2 (1.1) 648 (98.9) 0.53 0.13–2.20 0.373
Missing 17 (2.6) 399 (97.4) 1.21 0.67–2.19 0.520
Smoking
status:
Non-smoker 47 (2.3) 1999 (97.7) REFERENCE
Current
smoker
14 (1.5) 890 (98.5) 0.67 0.37–1.22 0.187
Ex-smoker 51 (2.9) 1678 (97.1) 1.28 0.87–1.90 0.209
Missing 3 (5.4) 52 (94.5) 2.37 0.76–7.39 0.130
≥1 consultations for LRTI in the 28 days prior to CAP
diagnosis:
Present 27 (5.1) 502 (94.9) 2.44 1.60–3.72 <0.001
Absent 88 (2.1) 4117 (97.9) REFERENCE
Antibiotics for LRTI in the 28 days prior to CAP
diagnosis:
Present 20 (4.8) 400 (95.2) 2.16 1.35–3.47 0.001
Absent 95 (2.2) 4219 (97.8) REFERENCE
Radiological assessment on index date:
Present 8 (3.5) 220 (96.5) 1.48 0.73–2.99 0.278
Absent 107 (2.4) 4399 (97.6) REFERENCE
(Continued)
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Table 2 (Continued).
CRB65 or 3 CRB65 Components
Recorded: n (%)
CRB65 Not
Recorded: n (%)
Risk Ratio 95% Conﬁdence
Intervals
p-Value
COPD before or on index date:
Present 17 (2.7) 622 (97.3) 1.11 0.67–1.85 0.683
Absent 98 (2.4) 3997 (97.6) REFERENCE
Asthma before/on index date:
Present 30 (2.5) 1245 (97.5) 0.96 0.63–1.44 0.836
Absent 85 (2.4) 3374 (97.6) REFERENCE
Chronic respiratory condition:
Present 13 (4.2) 299 (95.8) 1.80 1.03–3.18 0.039
Absent 102 (2.3) 4320 (97.7) REFERENCE
Bronchiectasis:
Present 7 (5.4) 122 (94.6) 2.31 1.11–4.87 0.025
Absent 108 (2.3) 4497 (97.7) REFERENCE
Cardiovascular disease:
Present 39 (3.1) 1224 (96.9) 1.41 0.96–2.06 0.075
Absent 76 (2.2) 3395 (97.8) REFERENCE
Ischemic heart disease:
Present 23 (4.0) 552 (96.0) 1.81 1.15–2.83 0.009
Absent 92 (2.2) 4067 (97.8) REFERENCE
Congestive heart failure:
Present 8 (3.0) 260 (97.0) 1.25 0.61–2.53 0.543
Absent 107 (2.4) 4359 (97.6) REFERENCE
Myocardial infarction:
Present 8 (2.8) 279 (97.2) 1.16 0.57–2.35 0.684
Absent 107 (2.4) 4340 (97.5) REFERENCE
Hypertension:
Present 1 (1.1) 86 (98.9) 0.47 0.07–3.32 0.725
Absent 114 (2.5) 4533 (97.5) REFERENCE
Diabetes
mellitus:
Present 22 (4.0) 528 (96.0) 1.80 1.14–2.84 0.011
Absent 93 (2.2) 4091 (97.7) REFERENCE
Rhinitis:
Active 11 (2.7) 390 (97.3) 1.12 0.61–2.08 0.686
Inactive 15 (2.2) 672 (97.8) 0.89 0.52–1.53 0.711
Absent 89 (2.4) 3557 (97.6) REFERENCE
(Continued)
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21.7–24.2%] vs 19.0% [95% CI: 17.8–20.3%]; p<0.001)
than in episodes referred to hospital. There was no signiﬁcant
difference in the proportion of episodes where CRB65 was
recorded between those managed in primary care (19, 0.4%
[95% CI: 0.24–0.63%]) and those resulting in a hospital
referral (12, 0.3% [95% CI: 0.16–0.55%]; p=0.63), though
Table 2 (Continued).
CRB65 or 3 CRB65 Components
Recorded: n (%)
CRB65 Not
Recorded: n (%)
Risk Ratio 95% Conﬁdence
Intervals
p-Value
Eczema:
Active 1 (4.3) 22 (95.7) 1.82 0.26–12.53 0.429
Inactive 31 (2.5) 1204 (97.5) 1.05 0.70–1.58 0.829
Absent 83 (2.4) 3393 (97.6) REFERENCE
Eosinophilia:
Present 28 (4.3) 620 (95.7) 2.03 1.34–2.03 <0.001
Absent 87 (2.1) 3999 (97.9) REFERENCE
Gastro-oesophageal reﬂux disease:
Active 35 (3.2) 1067 (96.8) 1.44 0.97–2.14 0.072
Inactive 7 (2.2) 318 (97.8) 0.98 0.45–2.10 0.950
Absent 73 (2.2) 3234 (97.8) REFERENCE
Abbreviations: LRTI, Lower respiratory tract infection; COPD, Chronic obstructive pulmonary disease.
Table 3 Results Of Logistic Regression Modelling Of Determinants Of CRB65 Or Three Or More Components Of CRB65 Recording
Recorded n/N (%) Odds Ratio 95% Conﬁdence Intervals p-Value
Year:
2009–2014 68/3994 (1.7) Reference
2015–2016 47/740 (6.4) 3.67 2.49–5.38 <0.001
Age group:
18–44 13/1050 (1.2) Reference
45–64 31/1399 (2.2) 1.64 0.87–3.28 0.141
65–84 51/1720 (3.0) 2.07 1.14–4.03 0.023
85+ 20/565 (3.5) 2.56 1.26–5.36 0.010
LRTI consultation in baseline:
Present – no antibiotics prescribed 8/117 (6.8) 3.47 1.50–7.01 0.001
Present – antibiotics prescribed 20/420 (4.7) 2.18 1.28–3.53 0.003
Absent 87/4197 (2.1) Reference
Diabetes mellitus:
Present 22/550 (4.0) 1.58 0.95–2.53 0.066
Absent 93/4186 (2.2) Reference
Eosinophillia:
Present 28/648 (4.3) 1.72 1.09–2.64 0.016
Absent 87/4086 (2.1) Reference
Abbreviation: LRTI, Lower respiratory tract infection.
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the median score was greater in those referred to hospital
(1.0 [IQR: 0.5–1.0] vs 2.0 [IQR: 1.0–2.0], p=0.04).
Discussion
This study demonstrates that, despite CRB65 scores being
incorporated into BTS guidelines in 20099 and NICE
guidelines in 2014,10 CRB65 scores are not well documen-
ted by primary care physicians for CAP patients managed
in primary care. CRB65 scores were completed on the day
of diagnosis in only 0.4% of episodes, in the 28-day base-
line period prior to diagnosis for 0.3% of episodes and in
the 28-day outcome period after diagnosis in one episode.
Table 4 Antibiotic Prescriptions On Day Of CAP Diagnosis By CRB65 Score At Index
CRB65 Score No CRB65 Score Recorded All Episodes
0 1 2 n (%)
Single antibiotic 5 9 2 4326 4342 (91.7)
Penicillin 2 6 1 2518 2527 (53.4)
Amoxicillin 1 5 1 1901 1908 (40.3)
Co-amoxiclav 1 1 0 585 587 (12.4)
Other 0 0 0 32 32 (0.7)
Macrolide 2 0 1 1136 1139 (24.1)
Clarithromycin 2 0 1 882 885 (18.7)
Erythromycin 0 0 0 232 232 (4.9)
Azithromycin 0 0 0 22 22 (0.5)
Tetracycline 1 3 0 417 421 (8.9)
Doxycycline 1 3 0 400 404 (8.5)
Other 0 0 0 17 17 (0.4)
Other 0 0 0 255 255 (5.4)
Multiple antibiotics 0 2 1 389 392 (8.3)
Amoxicillin and erythromycin 0 0 0 27 27 (0.6)
Amoxicillin and clarithromycin 0 2 1 179 182 (3.8)
Co-amoxiclav and erythromycin 0 0 0 4 4 (0.08)
Co-amoxiclav and clarithromycin 0 0 0 89 89 (1.9)
Other 0 0 0 90 90 (1.9)
Total 5 11 3 4715 4734
Note: Bold text and values are broad antibiotic classes, with the most frequently reported antibiotics in that class under them.
Table 5 Antibiotic Prescribing In Line With Proposed NICE Guidelines
CRB65 Score NICE Draft Guidelines Number of episodes, n (%)
0 First choice: Amoxicillin 1 (20.0)
Second choice: Clarithromycin, erythromycin or doxycycline 3 (60.0)
Other 1 (20.0)
Total 5
1–2 First choice: Amoxicillin and erythromycin or amoxicillin and clarithromycin 3 (21.4)
Second choice: Clarithromycin or azithromycin 1 (7.1)
Other 10 (71.4)
Total 14
No score listed NA: Those prescribed in line with CRB65 score 0–2 3643 (77.3)
NA: Prescribed other therapies 1072 (22.7)
Total 4734
Note: Data from NICE Guidelines.12
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No increase in CRB65 recording was observed following
the introduction of the BTS guidelines in 2009, and despite
improvements in CRB65 recording following the NICE
guidelines in 2014, CRB65 recording remained low
throughout the study period. The recording of the compo-
nents of the CRB65 score was also low, particularly
respiratory rate and confusion. The low level of confusion
recorded may reﬂect a reluctance to record an absence of
confusion, or the difﬁculties of determining mental status
in a short consultation. While the CRB65 score has good
predictive value,7,13 its utility may depend on the popula-
tion. A score of 1 in an otherwise healthy 65-year old may
not require consideration of hospitalization, while in the
elderly population confusion may be hard to differentiate
from other pre-existing conditions.15
The ﬁndings of our study are in line with a study of
CRB65 use in admission decisions in a hospital in South
Africa, where CRB65 was only being used in 1.6% of
patients.16 This study concluded that, had CRB65 been
used more frequently, fewer patients would have been
hospitalized. Other studies have also shown that CAP
severity scores are infrequently used in clinical practice.13
In our study, CRB65 was more likely to be recorded in
patients who were diagnosed with an LRTI in the 28 days
prior to CAP diagnosis, who were over 85 years, or had
eosinophilia. It may be therefore that CRB65 scores are
being used more frequently to stratify patients perceived to
be at increased risk of mortality. In addition to CRB65, other
indicators such as poor functional status,17 oxygenation18
and comorbidities19 are also predictive of severity.
Therefore, while CRB65 score recording was low, primary
care physicians are likely using a wide range of indicators to
inform their clinical judgement, including social factors20 not
captured in our study. In our study, clinicians recorded a
variety of additional indicators on the day of diagnosis for
patients managed in primary care: pulse rate was recorded in
10.7% of episodes, oxygen saturation was recorded in 7.1%
and blood tests were performed or requested in 5.4%.
Notably, performing a chest examination was poorly
recorded in our study (9.1%) possibly as this was considered
a routine investigation and physicians reported results
(57.4%) of the investigation instead.
While there was little difference in the proportion of epi-
sodes with CRB65 recorded between episodes managed in
primary care and those referred to hospital, episodes of CAP
managed in primary carewere less likely to have comorbidities
and were younger and where recorded had lower CRB65
scores than episodes resulting in referral to hospitalisation.
This suggests that despite the low level of CRB65 recording,
pneumonia in patientswith pre-existing risk factors for adverse
outcomes in pneumonia is more likely to be hospitalized.
Currently, NICE recommends that a ﬁve-day course of
amoxicillin is considered for treatment of low-severity
CAP, while dual antibiotic therapy of amoxicillin and a
macrolide and a 7–10-day duration should be considered
for moderate severity.11 The newly published draft NICE
guidelines for antimicrobial prescribing for CAP12 provide
more detail, providing alternative therapy in the event of
penicillin allergy, estimated to affect approximately 10%
of the population,21 and embedding the CRB65 scores into
the decision-making process. In our study, amoxicillin was
prescribed on the day of diagnosis as single antibiotic in
40.3% of episodes and in combination with a macrolide in
4.4% of episodes. While only a small number of episodes
had CRB65 scores recorded, the observed differences
between the draft NICE guidelines12 and the prescribing
patterns in this study suggest a change in practice may be
required. The majority of episodes in our study consisted
of one consultation, suggesting that follow-up after anti-
biotic prescription is uncommon.
A recent study has suggested that a substantial propor-
tion of antibiotic prescriptions given for common infec-
tions in primary care are for longer duration than
guidelines suggest.22 Despite the NICE guidelines recom-
mending that a ﬁve-day course of amoxicillin for low-
severity CAP, the majority of prescriptions in our study
were for seven days, as is recommended for low-severity
CAP in the 2009 BTS guidelines.9,23
The main limitation of this study is the observational
nature. As an observational study based on medical records,
this study is open to misclassiﬁcation bias. A large propor-
tion of identiﬁed CAP consultations (60.5%) did not have
antibiotic prescriptions recorded on the day of diagnosis.
Because prescriptions are generated automatically from the
computer, antibiotic prescribing data are unlikely to be
incomplete for such a large proportion of patients, although
they may be missing for those treated at home or out of
hours. Other potential reasons for the low rate of recorded
antibiotic prescribing include misclassiﬁcation of CAP or
poor recording of hospital referral. It is the authors' belief
that the latter is the most plausible, and therefore these cases
were excluded from the analysis. Patients referred to sec-
ondary care may receive antibiotic therapy in secondary
rather than primary care and therefore antibiotic prescrip-
tions may not be recorded in primary care records.
Antibiotic prescription was markedly less recorded in
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those with hospitalization recorded (95/3819; 2.5%) com-
pared to those managed in primary care (4734/26,536;
17.8%). Furthermore, it is unknown whether the low
recording of CRB65 scores and the components of CRB65
is due to physicians not using these scores in primary
practice, or whether they are used but not routinely
recorded.
Conclusion
While previous studies have shown that CRB65 scores are
predictive of 30-day mortality, this is the ﬁrst study in the
UK to document the recording of CRB65 in primary care.
We observed a low level of CRB65 recording in this study
for patients managed in primary care and referred to sec-
ondary care. Further work is needed to assess feasibility of
using CRB65 scores in primary care, GPs awareness of the
inclusion of these scores in both the BTS and NICE guide-
lines and potential barriers to use of CRB65.
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